Editas Medicine, Inc. (EDIT): Price and Financial Metrics
EDIT Price/Volume Stats
Current price | $7.72 | 52-week high | $11.91 |
Prev. close | $8.13 | 52-week low | $6.08 |
Day low | $7.70 | Volume | 2,658,300 |
Day high | $8.15 | Avg. volume | 1,880,087 |
50-day MA | $8.35 | Dividend yield | N/A |
200-day MA | $8.66 | Market Cap | 631.60M |
EDIT Stock Price Chart Interactive Chart >
EDIT POWR Grades
- Growth is the dimension where EDIT ranks best; there it ranks ahead of 73.34% of US stocks.
- The strongest trend for EDIT is in Growth, which has been heading up over the past 26 weeks.
- EDIT ranks lowest in Stability; there it ranks in the 3rd percentile.
EDIT Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for EDIT is 0.07 -- better than just 12.24% of US stocks.
- With a price/sales ratio of 31.43, EDITAS MEDICINE INC has a higher such ratio than 95.59% of stocks in our set.
- With a year-over-year growth in debt of 62.48%, EDITAS MEDICINE INC's debt growth rate surpasses 88.46% of about US stocks.
- If you're looking for stocks that are quantitatively similar to EDITAS MEDICINE INC, a group of peers worth examining would be FUSN, GSIT, HYLN, SLDP, and ITOS.
- EDIT's SEC filings can be seen here. And to visit EDITAS MEDICINE INC's official web site, go to www.editasmedicine.com.
EDIT Valuation Summary
- In comparison to the median Healthcare stock, EDIT's price/sales ratio is 1427.27% higher, now standing at 33.6.
- EDIT's price/sales ratio has moved down 365.2 over the prior 96 months.
Below are key valuation metrics over time for EDIT.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
EDIT | 2023-12-29 | 33.6 | 2.3 | -4.2 | -3.7 |
EDIT | 2023-12-28 | 34.3 | 2.3 | -4.3 | -3.8 |
EDIT | 2023-12-27 | 34.4 | 2.4 | -4.3 | -3.8 |
EDIT | 2023-12-26 | 35.4 | 2.4 | -4.5 | -3.9 |
EDIT | 2023-12-22 | 35.9 | 2.5 | -4.5 | -4.0 |
EDIT | 2023-12-21 | 34.3 | 2.3 | -4.3 | -3.8 |
EDIT Growth Metrics
- The 2 year revenue growth rate now stands at 6.74%.
- Its year over year revenue growth rate is now at -71.79%.
- Its year over year cash and equivalents growth rate is now at -40.58%.
The table below shows EDIT's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 25.644 | -169.658 | -201.13 |
2022-06-30 | 31.799 | -162.439 | -184.486 |
2022-03-31 | 25.816 | -163.551 | -186.289 |
2021-12-31 | 25.544 | -163.803 | -192.502 |
2021-09-30 | 24.494 | -169.321 | -213.565 |
2021-06-30 | 81.138 | -183.337 | -166.664 |
EDIT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- EDIT has a Quality Grade of D, ranking ahead of 12.21% of graded US stocks.
- EDIT's asset turnover comes in at 0.12 -- ranking 248th of 682 Pharmaceutical Products stocks.
- SMMT, SAGE, and VSTM are the stocks whose asset turnover ratios are most correlated with EDIT.
The table below shows EDIT's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.120 | 1 | -0.458 |
2021-03-31 | 0.140 | 1 | -0.450 |
2020-12-31 | 0.158 | 1 | -0.468 |
2020-09-30 | 0.164 | 1 | -0.447 |
2020-06-30 | 0.065 | 1 | -0.704 |
2020-03-31 | 0.057 | 1 | -0.806 |
EDIT Price Target
For more insight on analysts targets of EDIT, see our EDIT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $50.75 | Average Broker Recommendation | 1.79 (Moderate Buy) |
Editas Medicine, Inc. (EDIT) Company Bio
Editas Medicine Inc. operates as a genome editing company. It focuses on translating its genome editing technology into a class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a range of diseases at the genetic level. Editas Medicine Inc. was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest EDIT News From Around the Web
Below are the latest news stories about EDITAS MEDICINE INC that investors may wish to consider to help them evaluate EDIT as an investment opportunity.
Editas Just Caught a Break Thanks to Vertex PharmaceuticalsEditas isn't out of the woods yet, but it's better off than before. |
Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 23%Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders will have a reason to smile today, with the analysts making... |
The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeuticsbluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog. |
Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent Newsbluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news. |
Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy. |
EDIT Price Returns
1-mo | -5.28% |
3-mo | -24.39% |
6-mo | -3.50% |
1-year | -5.85% |
3-year | -82.84% |
5-year | -68.80% |
YTD | -23.79% |
2023 | 14.21% |
2022 | -66.59% |
2021 | -62.13% |
2020 | 136.78% |
2019 | 30.15% |
Continue Researching EDIT
Want to do more research on Editas Medicine Inc's stock and its price? Try the links below:Editas Medicine Inc (EDIT) Stock Price | Nasdaq
Editas Medicine Inc (EDIT) Stock Quote, History and News - Yahoo Finance
Editas Medicine Inc (EDIT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...